Table 1 Sensitivity of cell lines to gemcitabine alone or in combination with MK-8776
A. Gemcitabine and MK-8776 0–24 h | |||
|---|---|---|---|
Cell line | IC50(nmol/L) | ||
Gem alone | Gem + 200 nmol/L MK-8776 | Gem + 2 μmol/L MK-8776 | |
U251 | 36.6 ± 8.8 | 15 ± 5.5 (2.4) | 6.5 ± 1.5 (5.6) |
HCT115 | 25 ± 5 | 13.8 ± 1.3 (1.8) | 5.1 ± 1.1 (4.9) |
SW620 | 83.3 ± 16 | 30 ± 0 (2.8) | 4.8 ± 0.9 (17.4) |
IGROV-1 | 25 ± 5 | 5.2 ± 1.1 (4.8) | 3.5 ±1.5 (7.1) |
HCT116 | 13.8 ± 1.3 | 5.5 ± 0.5 (2.5) | 3.3 ± 0.3 (4.2) |
MCF10A | 13 ± 6.1 | 5.2 ± 2.4 (2.5) | 2.8 ± 1.1 (4.6) |
MiaPaCa-2 | 26.5 ± 4.3 | 4.2 ± 0.8 (6.3) | 2.2 ± 1.2 (12.0) |
MDA-MB-231 | 18.5 ± 7.1 | 4.4 ± 0.81 (4.2) | 1.5 ± 0.44 (12.3) |
HCC2998 | 15 ± 5 | 3.8 ± 1.3 (3.9) | 1.5 ± 0.4 (10.0) |
U87 | 7.5 ± 1.3 | 2.7 ± 0.4 (2.8) | 1.5 ± 0.3 (5.0) |
MDA-MB-435 | 8.6 ± 3.2 | 1.5 ± 1.5 (5.7) | 0.4 ± 0 (21.5) |
SNB19 | 10 ± 3.5 | 1.3 ± 0.08 (7.7) | 0.15 ± 0.03 (66.7) |
U20S | 32.5 ± 2.5 | 10.5 ± 4.5 (3.1) | DEAD |
A498 | 22.5 ± 2.5 | 3.5 ± 1.5 (6.4) | DEAD |
TK10 | 3.4 ± 1.6 | 2.8 ± 1.3 (1.2) | DEAD |
AsPC-1 | 14 ± 1 | 3.3 ± 0.2 (4.2) | DEAD |
B. Gemcitabine 0–24 h; MK-8776 18–24 h | |||
U251 | 36.6 ± 8.8 | 32.5 ± 2.5 (1.1) | 12.5 ± 2.5 (2.9) |
MDA-MB-231 | 18.5 ± 7.1 | 12.5 ± 5.5 (1.5) | 4.6 ± 0.8 (4.0) |
U87 | 7.5 ± 1.3 | 5 ± 0.6 (1.5) | 2.8 ± 0.16 (2.7) |
MDA-MB-435 | 8.6 ± 3.2 | 8 ± 2 (1.1) | 0.77 ± .73 (11.2) |
AsPC-1 | 14 ± 1 | 7.8 ± 2.2 (1.8) | 1.7 ± 0.23 (8.2) |
C. Gemcitabine 0–6 h; MK8776 18–24 h | |||
U251 | 250 ± 51 | 187 ± 38 (1.3) | 113 ± 18.5 (2.2) |
MiaPaCa-2 | 175 ± 25 | 90 ± 35 (1.9) | 39 ± 1 (4.5) |
MDA-MB-231 | 60.5 ± 10.3 | 35 ± 9.6 (1.7) | 19.2 ± 2.3 (3.2) |
U87 | 12.6 ± 3.9 | 9 ± 2.1 (1.4) | 5.3 ± 0.9 (2.4) |
MDA-MB-435 | 41.6 ± 19.7 | 22.5 ± 7.5 (1.8) | 5.5 ± 2.5 (7.6) |
SNB19 | 75 ± 0 | 35 ± 5 (2.1) | 16.5 ± 1.5 (4.5) |
AsPC-1 | 115 ± 11.9 | 53.3 ± 6.7 (2.2) | 12 ± 1.7 (9.6) |